Full Prescribing Information
 
Important Safety Information
Wynzora® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% logo
hamburger menu close icon hamburger menu close icon

Join the celebration!

Sign up today to receive updates on Wynzora

Get updates on Wynzora

  • Dermatologist
  • NP/PA
  • Other

*Required fields.

I authorize MC2 Therapeutics, EPI Health, and companies working with MC2 Therapeutics and EPI Health to contact me by mail, email, fax, telephone call, and text message (including autodialed and prerecorded calls and messages) for marketing purposes or otherwise provide me with information about their products, services, and programs or other topics of interest, conduct market research, or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that any information that I provide may be used by MC2 Therapeutics, EPI Health, and companies working with MC2 Therapeutics and EPI Health to help develop new products, services, and programs. I understand that my consent is not required as a condition of receiving any product information or services from MC2 Therapeutics and/or EPI Health. MC2 Therapeutics, EPI Health, and companies working with MC2 Therapeutics and EPI Health will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission.
I am interested in being contacted by a sales representative.
I agree to the statement above and have read and understand the Terms and Conditions and Privacy Policy.*
arrow

Important safety information

INDICATION: Wynzora® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older. ADVERSE EVENTS: In the pivotal trial, the most common adverse reactions (≥1%) were: upper respiratory infection (7%), headache (2%), and application site infection (1%). WARNINGS AND PRECAUTIONS: For topical use only. Patients should not use more than 100g of Wynzora® Cream per week. Do not use near or in the mouth, eyes or intravaginally. Avoid using Wynzora® Cream on the face, groin or armpits, or if they have atrophy at the treatment site. Discontinue use once plaque psoriasis is under control or at 8 weeks. Do not use Wynzora® Cream with occlusive dressings. Hypercalcemia and hypercalciuria have been observed with topical use of calcipotriene. Wynzora® Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment. Wynzora® Cream may cause vision problems, including increasing the risk of cataracts and glaucoma. It is not known if Wynzora® Cream may harm your unborn baby. Breastfeeding women should not apply Wynzora® Cream directly to the nipple or areola; it is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.

Please see Full Prescribing Information for Wynzora.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

pink close icon

Watch how PADTM Technology optimizes absorption of Cal and BDP3

Play button for Wynzora and PAD™ Technology mechanism of action video
Wynzora MOA video icon

Close modal